
- BioPharm International, February 2024
- Volume 37
- Issue 2
- Pages: 6
J.P. Morgan Losing Weight
Given its positioning at each new year’s commencement, the J.P. Morgan Healthcare conference helps establish the tone with which the pharmaceutical industry is viewed.
Given its positioning at each new year’s commencement, the J.P. Morgan Healthcare conference helps establish the tone with which the pharmaceutical industry is viewed. It is rare for major new announcements to be made at the conference; rather, its prominence is due to its capacity to sum up and condense the lessons learned from the past year’s fray.
As such, both Lisa Gill, senior analyst covering Health Care Services, and Chris Schott, senior analyst at J.P. Morgan covering US Diversified Biopharma, emphasize the salience of the current generation of weight loss drugs. Schott stated that, from an investment perspective, due to pharmaceuticals underperforming in 2023, “investor sentiment is pretty bearish for 2024 … as [the sector] is a well-positioned group, at record low valuations” (1). Schott goes on to say, “the GLP-1 weight loss drugs are projected to hit $100 billion in prescription sales by early 2030s, making it the largest therapeutic market we’ve ever seen, … and to alleviated bottlenecks, production capacity is expected to double in 2024, and rise again by 50% in 2025” (1).
While recaps are certainly useful, it is salutary to point out Pharmaceutical Technology was investigating GLP-1 performance in 2022, and asking, are obesity drugs the next blockbusters?
References
- Gill, L; and Schott, C. 42nd Annual J.P. Morgan Healthcare Conference, J.P. Morgan Health Events website,
https://www.jpmorgan.com/about-us/events-conferences/health-care-conference (accessed Jan. 16, 2024). - Necdina, M. Are Obesity Drugs the Next Blockbusters? PharmTech.com. Nov. 2. 2022.
About the Author
Mike Hennessy Jr. is the President and CEO of MJH Life Sciences.
Article Details
BioPharm International
Volume 37, No. 2
February 2024
Page 6
Citation
When referring to this article, please cite it as Hennessy, M. J.P. Morgan Losing Weight. BioPharm International 2024 37 (2) 6.
Articles in this issue
over 1 year ago
Bracing for a Future Wave of Advanced Therapiesover 1 year ago
Developing CAR-T Cell Therapies for the Futureover 1 year ago
Choosing the Right Excipients for MSC and iPSC Therapiesover 1 year ago
Milestone Approval to Steady Stream, Gene Editing Revs Upover 1 year ago
Stepping Up Process Control with Single-Use Systemsover 1 year ago
Increasing mRNA Product Stability with Lyophilizationover 1 year ago
Addressing PK/PD Study Design Early in Developmentover 1 year ago
Computer Validation Confirms EvidenceNewsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.